The fertility industry: profiting from vulnerability
By Editorial Staff,
The Lancet
| 07. 20. 2024
Image by DrKontogianniIVF from Wikimedia Commons
Despite major advances in securing sexual and reproductive rights globally, one aspect is continually neglected: infertility. Evolving gender norms and financial precariousness have led to delayed childbearing, which increases infertility in both males and females. An estimated one in six people are affected. However, there is insufficient awareness about fertility decline, the risk factors, and viable treatments for infertility. Assisted reproductive technologies (ARTs), particularly in-vitro fertilisation (IVF), help many. Almost 50 years after the birth of the first baby conceived by IVF was reported in The Lancet, this method is used in 9% of births in some high-income countries. Such advances have enabled millions to have children. However, the fertility sector has now spawned an entire industry that risks exacerbating rather than alleviating the psychological toll of infertility and does little to help reduce inequities in access to quality care.
Medical advances have helped increase the effectiveness of IVF. In women aged 35–37 years in the UK, the livebirth rate per embryo transferred increased from 6% in 1991 to 25% in 2019...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...